The ALL Hub was pleased to speak with Sabina Chiaretti, Sapienza University, Rome, IT. We asked, What are the key considerations when determining the number and duration of blinatumomab treatment cycles? In this interview, Chiaretti discusses the key considerations when determining the number and duration of blinatumomab treatment cycles in B-ALL. She highlights factors that may inform treatment duration, including Philadelphia chromosome status, MRD response and genomic features. She also discusses clinical evidence supporting different treatment schedules across B-ALL treatment settings and the ongoing investigations into the optimal number and duration of blinatumomab cycles. Intended for healthcare professionals. This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
","author_name":"Scientific Education Support"}